Health Trials

About this trial

ECMO (extracorporeal membrane oxygenation) is a life-saving device, used in intensive care to treat severe respiratory or cardiac failure. However, it carries a high risk of serious life-threatening bleeding.

Bleeding complications have been attributed to coagulopathy triggered either by the underlying pathology or by the extracorporeal circuit itself, as well as excessive or inappropriate anticoagulation initiated to prevent thrombotic complications.

The objective of this cohort is to confirm the interest of the evolution of D-dimers as a prognostic marker of serious bleeding events in patients on veno-venous (VV) or veno-arterial (VA) ECMO, and to determine the threshold.

Eligibility criteria

Qualifiers

Male or female ≥ 18 years of age

Hospitalized patient in intensive care

Implementation of a VV or VA ECMO for less than 24 hours

Patient affiliated to a social protection health insurance scheme

Disqualifiers

Patient on veno-arterial ECMO after cardiac, cardiopulmonary surgery or after placement of a left or biventricular cardiac assist device

Congenital hemostasis disorder or anatomical abnormality predisposing to bleeding

Dying patient on the day of inclusion

Patient under judicial protection

Trial design

Treatments tested in this trial

  • Blood sampling collection

Treatment groups

No treatment groups listed

Locations

1
Service de Médecine Intensive - Réanimation Nouvel Hôpital Civil67098, Strasbourg France

Sponsors and collaborators

University Hospital, Strasbourg, France

Lead sponsor

Source ClinicalTrials.gov